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Improvements in the diagnostic and thera- 
peutic approach to patients with epilepsy have 
substantially changed the outcome, and conse- 
quently, the socio-cultural implications of the 
disease. Up to 90% of patients from different 
countries have prolonged periods of seizure 
remission 1-3 and about 60% of those who have 
been taken off treatment remain seizure-free 
at two years 4. This brings a considerable pro- 
portion of cases back to normal ife. The every- 
day life risks (morbidity, accidents, etc.) for the 
majority of patients with epilepsy are therefore 
not expected to be different from those of the 
general population. However, the improve- 
ment in the medical approach to epilepsy has 
not yet been followed by an equal improvement 
in the management of the social and legal 
aspects. Patients with epilepsy are still 
thought o be at higher risk of morbidity and 
accidents. This belief may influence the atti- 
tudes of lay people towards epilepsy and have a 
significant impact on individual patients' qual- 
ity of life. Insurance premiums are generally 
higher for patients with epilepsy, under the 
belief that the disease interferes with everyday 
activities through the patient's life. 
Available knowledge of the everyday life 
risks in patients with epilepsy is inadequate 
because published reports are far from conclus- 
ive. This was clearly stated in a recent work- 
shop on epilepsy, risks and insurance 5. Based 
on the results of that workshop, the Inter- 
national Bureau for Epilepsy (IBE) set up an 
ad-hoc Commission on Epilepsy, Risks and In- 
surance (C. Cornaggia (Chairman) and E. 
Beghi, Italy; W.A. Hauser, USA; J.H. Loeber 
and A.E.H. Sonnen, Holland; R. Thorbecke, 
Germany) to draft guidelines for the assess- 
ment of everyday life risks based on the results 
in the literature 8. In brief, patients with epi- 
lepsy may be at higher risk of early death, 
suicide and psychiatric hospital admission, but 
they do not seem at higher isk of having traf- 
fic accidents or, when epilepsy is controlled, of 
unfitness to work and early retirement. A
greater risk of accidents at work among people 
with epilepsy was occasionally reported, due to 
motor impediments, not secondary to the dis- 
order per  se. Data are lacking on the risk of 
morbidity, days lost from work and treatment 
in hospital. 
The lack of high-quality information about 
the everyday risks in epilepsy depends on the 
scarcity of reports and of studies conducted 
with proper methods. The risks attributable to
epilepsy can be precisely calculated by compar- 
ing the frequency of each measurable event in 
patients and in a matched control population. 
As epilepsy presents fairly similar character- 
istics in the developed countries, special prob- 
lems with regard to everyday life risks are 
likely to be similar within the European 
Union, and a sizeable sample of patients and 
matched controls is needed to investigate hese 
points. 
The scarcity of the available data prompted a 
multinational cohort study on everyday life 
risks in pediatric and adult patients with epi- 
lepsy and in matched non-epileptic ontrols. 
Firstly, diagnosed patients with idiopathic and 
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remote symptomatic epilepsies residing in the 
areas served by the participating centres will 
be selected and followed up for 24 months. The 
following variables will be collected and ana- 
lysed in patients and controls: medical contacts 
and underlying illnesses, accidents (traffic, 
domestic, work), hospital admissions and days 
off work (off school). 
Seven European countries (Italy, Germany, 
France, United Kingdom, Denmark, Holland 
and Spain) will participate in the study provid- 
ing a cohort of about 1000 patients and 1000 
matched controls. At the end of the study, data 
from these international sources will be de- 
livered to insurance companies and any other 
private or governmental agency dealing with 
patients with epilepsy. The study has been 
funded by the European Union (Biomed I Pro- 
gram) which has promoted concerted action be- 
tween members of European countries having 
common interests and objectives in health 
care. 
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